Search
Now showing items 61-70 of 519
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
(2016-09)
Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that ...
Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features
(FERRATA STORTI FOUNDATION, 2010-07)
Background Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recognized as a provisional entity in the 2008 update of the WHO Classification. Additional work is required to review this ...
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
(2018-09-04)
Background Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ...
Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer.
(2018-03)
<b/> Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms ...
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
(2017-05-15)
The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation ...
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
(2019-06-10)
Targeted inhibition of the ERK-MAPK pathway, upregulated in a majority of human cancers, has been hindered in the clinic by drug resistance and toxicity. The MRAS-SHOC2-PP1 (SHOC2 phosphatase) complex plays a key role in ...
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
(2019-11)
Background For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether ...
DECONVOLVING CONVOLUTIONAL NEURAL NETWORK FOR CELL DETECTION
(IEEE, 2019-01-01)
NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL
(FERRATA STORTI FOUNDATION, 2016-06-01)